Alkermes Announces Positive Topline Results From REVITALYZ Phase 3 Study Evaluating LUMRYZ (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ (sodium oxybate) extended-release oral suspension in adults with idiopathic...